Significantly Improved UPSIT Score vs Placebo at Week 24 (Key Secondary Endpoint) With Sustained Improvement Through Week 52 (Other Secondary Endpoint)3

Analysis of change at Week 52 was not multiplicity controlled; result is descriptive.

SINUS-52

CHANGE IN UPSIT SCORE THROUGH WEEK 52

DUPIXENT® (dupilumab) demonstrated a rapid and sustained sense of smell improvement as measured by UPSIT, with a 71% improvement at week 52 vs. a 6% worsening with placebo
71%
Improvement

at Week 52 with DUPIXENT (baseline score 13.46) vs 6% worsening with placebo (baseline score 13.78) (LSM difference: 10.30 [95% CI: 8.50, 12.10])3

  • DUPIXENT 300 mg Q2W +
    INCS (n=150)
  • Placebo + INCS (n=153)

Analysis of change at Week 52 was not multiplicity controlled; result is descriptive.

LSM
change from
baseline in
UPSIT score
  • 11
  • 10
  • 9
  • 8
  • 7
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
  • 0
  • -1
  • -2
Weeks
  • 0
  • 2
  • 4
  •  
  •  
  •  
  •  
  •  
  • 16
  •  
  •  
  •  
  • 24
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 52
67%

OF THE TOTAL IMPROVEMENT IN SENSE OF SMELL WAS SEEN AFTER THE FIRST DOSE, AS MEASURED AT WEEK 23,b

bChange in UPSIT score at Week 2 (LSM difference vs placebo: 5.36 [95% CI: 3.62, 7.10]).3

 
72%

IMPROVEMENT AT WEEK 24 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (9.71 compared with a baseline score of 13.53) vs 6% worsening with placebo + INCS (n=153) (-0.81 compared with a baseline score of 13.78) (LSM difference: 10.52 [95% CI: 8.98, 12.07]) in SINUS-523

63%

REDUCTION IN THE
NUMBER OF PATIENTS
WITH ANOSMIA3,4

  • 79% (n=228/287, pooled DUPIXENT arms) of patients taking DUPIXENT 300 mg Q2W + INCS had anosmia at baseline, which was reduced to 30% (n=84/280, pooled DUPIXENT arms) at Week 24 in SINUS-523,4
    • There was almost no change with placebo: 76.7% (n=115/150 total patients) of patients taking placebo + INCS had anosmia at baseline, which was reduced to 76.6% (n=111/145 total patients) at Week 24 in SINUS-523,4

University of Pennsylvania Smell Identification Test (UPSIT) score (range 0 to 40): higher score indicates improvement.

Back to efficacy and safety overview
See nasal congestion score

Explore the Safety Data and Study Designs

View Safety Data
SEE THE FULL STUDY DESIGNS
Dosage and
Administration
See the recommended dosing and administration options for patients on DUPIXENT.
Explore ADMINISTRATION Options